Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Prior treatment

• Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression.
• History of hepatitis B or hepatitis C currently receiving ongoing antiviral therapy.
  • Any known uncontrolled cardiovascular disease at the time of Screening that, in the investigator's opinion, renders the participant ineligible
• History of hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening.
• History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or any other known bone marrow failure syndrome.
• Participant has received stem cell transplant within 90 days before Screening.
• Participant has received a systemic biologic agent for treatment of the disease under study within 28 days of LD, other systemic anti-cancer therapy within 10 days or 5 half-lives (whichever is shorter) of LD, and no pulse steroid for disease control within 3 days of LD.
• Radiotherapy within 4 weeks before Screening.
• Participant has received live vaccine within 4 weeks before Screening. Note: Non-live virus vaccines are not excluded.
• Participant has received CD19-directed therapy other than autologous CD19-directed CAR T therapy within 90 days of the anticipated start date of LD.
  • Additional criteria apply.

Other illness

• No active CNS disease, excluding PCNSL
• History of another primary malignancy
• Any form of primary immunodeficiency (for example, severe combined immunodeficiency disease).
• History of severe immediate hypersensitivity reaction to any of the agents used in this study.
• Presence of a CNS disorder that, in the opinion of the investigator, renders the participant ineligible for treatment.
• Active uncontrolled autoimmune disease requiring active immunosuppression at the time of Screening (excluding participants needing steroids for physiologic replacement).
• Participant has active graft-versus-host disease (GvHD) symptoms.

Other

• Criteria for B-ALL:
• Burkitt cell (L3 ALL) or mixed-lineage acute leukemia.
  • Criteria for NHL:
• Active hemolytic anemia.
  • Criteria for B-ALL and NHL:
• Presence of pleural/peritoneal/pericardial catheter, as well as permeant biliary and ureteral stents (does not apply to intravenous lines).

• Criteria for B-ALL:
• Participant has confirmed unequivocal r/r CD19+ B-ALL.
  • Criteria for NHL and CLL/SLL:
• Participant has unequivocal aggressive CD19+ r/r B-cell NHL that is confirmed by tumor biopsy tissue from last relapse after CD19-directed therapy.
  • For Phase 1 Dose Escalation:
• Diffuse large B-cell lymphoma (DLBCL) including Richter's transformation
• Follicular lymphoma (FL) including Grade 3 or transformed FL
• High-grade B-cell lymphoma (HGBCL)
• Primary mediastinal lymphoma
  • For Phase 1b Dose Expansion (CAR T-relapsed cohort):
• DLBCL not otherwise specified (NOS)
• HGBCL
• DLBCL transformed from the following indolent lymphoma subtypes (FL, Marginal Zone lymphoma \[MZL\], and Waldenstrom's Macroglobulinemia \[WM\])
• Other large B-cell lymphoma (LBCL) subtypes may be enrolled with approval from the Medical Monitor.
• Participants previously treated with CD19-directed autologous CAR T therapies have received no more than 2 lines of therapy after administration of their previous CAR T product.
• For the expansion CAR T-relapsed cohort only: Participants must have received autologous CD19-directed CAR T therapy and demonstrated clinical response to the treatment at Day 28 or later, followed by relapse or progression.
  • For Phase 1b dose expansion (CAR T-naive cohort and Con-BTKi cohort):
  • For indication with an approved autologous CAR T-cell therapy, participants must be ineligible for or unable to access autologous CAR T-cell therapy.
• DLBCL NOS
• DLBCL transformed from the following indolent lymphoma subtypes (FL, MZL, and WM)
• HGBCL
• FL (Grade 1-3a)
• MZL that is fluorodeoxyglucose (FDG)-avid on positron emission tomography (PET) scan
• WM
• CLL/SLL
• Primary central nervous system (CNS) lymphoma (PCNSL)
• Other LBCL subtypes may be enrolled with approval from the Medical Monitor.
• Participant must have received at least 1-2 prior lines of therapy, depending on histological subtype but no more than 7 systemic lines of anti-cancer therapy.
  • Participants enrolling into the Con-BTKi cohort must:
• Be receiving a BTKi (as a monotherapy or combination therapy) as the last, systemic anti-cancer regimen before study entry. Alternatively, if previously refractory to one or more BTK inhibitor(s) and the last systemic anti-cancer therapy before study entry did not include a BTKi, one of the previous BTK inhibitors may be used.
• Have radiologic or clinical disease progression while on the BTKi
• Agree to remain on BTKi therapy during the protocol-defined BTKi treatment window
• Have been tolerant to BTKi therapy
  • Criteria for both B-ALL, NHL, and CLL/SLL:
• Eastern Cooperative Oncology Group performance status score of 0 or 1.
• An estimated life expectancy of at least 12 weeks according to the investigator's judgment.
• Seronegative for human immunodeficiency virus antibody.
• Participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function.